Research programme: TWEAK receptor/TRAIL ligand fusion protein - KAHR Medical
Alternative Names: KAHR-101Latest Information Update: 22 Feb 2023
At a glance
- Originator KAHR Medical
- Class Proteins
- Mechanism of Action T lymphocyte inhibitors; TNF-related apoptosis-inducing ligand receptor antagonists; TNFSF12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Solid tumours
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Autoimmune disorders in Israel (unspecified route)
- 22 Feb 2023 Discontinued - Preclinical for Solid tumours in Israel (unspecified route)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Solid-tumours in Israel